Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Q3 2025 value amounting to 0.69%.

  • Rocket Pharmaceuticals' Return on Capital Employed rose 300.0% to 0.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.54% for FY2024, which is 300.0% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.69% for Q3 2025, which was up 300.0% from 0.66% recorded in Q2 2025.
  • Rocket Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.28% during Q1 2021, with a 5-year trough of 0.72% in Q3 2024.
  • Its 5-year average for Return on Capital Employed is 0.51%, with a median of 0.51% in 2022.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -1900bps in 2024, then skyrocketed by 300bps in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Return on Capital Employed stood at 0.34% in 2021, then crashed by -48bps to 0.5% in 2022, then increased by 3bps to 0.49% in 2023, then tumbled by -34bps to 0.65% in 2024, then decreased by -6bps to 0.69% in 2025.
  • Its Return on Capital Employed stands at 0.69% for Q3 2025, versus 0.66% for Q2 2025 and 0.58% for Q1 2025.